Viatris Inc.

WBAG:VTRS Stock Report

Market Cap: €15.2b

Viatris Valuation

Is VTRS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VTRS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VTRS (€12.82) is trading below our estimate of fair value (€54.94)

Significantly Below Fair Value: VTRS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTRS?

Key metric: As VTRS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VTRS. This is calculated by dividing VTRS's market cap by their current revenue.
What is VTRS's PS Ratio?
PS Ratio1.1x
SalesUS$15.05b
Market CapUS$15.82b

Price to Sales Ratio vs Peers

How does VTRS's PS Ratio compare to its peers?

The above table shows the PS ratio for VTRS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.4x
RPRX Royalty Pharma
5.2x7.2%US$15.6b
000538 Yunnan Baiyao GroupLtd
2.6x6.4%CN¥103.6b
MANKIND Mankind Pharma
9.3x18.4%₹1.0t
CIPLA Cipla
4.6x8.2%₹1.2t
VTRS Viatris
1.1x-1.1%€15.8b

Price-To-Sales vs Peers: VTRS is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (5.4x).

Price to Sales Ratio vs Industry

How does VTRS's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

23 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x7.4%
VTRS Viatris
 1.1x-1.1%US$15.82b
VTRS 1.1xIndustry Avg. 2.9xNo. of Companies35PS0612182430+
23 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x15.8%
VTRS Viatris
 1.1x53.5%US$15.82b
No more companies

Price-To-Sales vs Industry: VTRS is good value based on its Price-To-Sales Ratio (1.1x) compared to the European Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is VTRS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTRS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VTRS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VTRS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€12.82
€12.43
-3.1%
8.9%€14.25€11.40n/a8
Nov ’25€10.75
€11.81
+9.9%
9.7%€13.74€10.07n/a8
Oct ’25€10.45
€11.81
+13.1%
9.7%€13.74€10.07n/a8
Sep ’25€10.80
€11.81
+9.4%
9.7%€13.74€10.07n/a8
Aug ’25€11.08
€11.63
+5.0%
10.3%€13.79€10.11n/a8
Jul ’25€9.88
€11.43
+15.6%
6.9%€12.91€10.14n/a8
Jun ’25€9.68
€11.43
+18.1%
6.9%€12.91€10.14n/a8
May ’25€10.90
€11.65
+6.9%
7.0%€13.16€10.34n/a9
Apr ’25€10.94
€11.49
+5.1%
7.0%€12.98€10.20n/a9
Mar ’25€11.50
€11.03
-4.1%
9.6%€12.92€9.23n/a9
Feb ’25€10.77
€10.83
+0.6%
11.1%€12.93€9.23n/a9
Jan ’25€9.81
€10.52
+7.3%
12.7%€12.68€8.15n/a9
Dec ’24€8.48
€10.64
+25.4%
13.5%€12.83€8.25n/a8
Nov ’24€8.39
€11.01
+31.1%
13.9%€13.13€8.44€10.758
Oct ’24€9.46
€11.95
+26.3%
11.2%€14.16€9.44€10.459
Sep ’24€10.06
€11.36
+12.9%
12.0%€13.69€9.12€10.809
Aug ’24€9.28
€11.31
+21.9%
12.0%€13.75€9.17€11.089
Jul ’24€9.09
€11.64
+28.2%
11.9%€13.96€9.31€9.8810
Jun ’24€8.52
€11.46
+34.4%
11.8%€13.58€9.06€9.689
May ’24€8.22
€11.46
+39.4%
11.8%€13.58€9.06€10.909
Apr ’24€8.92
€12.46
+39.7%
17.3%€16.79€9.33€10.9411
Mar ’24€10.63
€12.63
+18.9%
16.7%€17.01€9.45€11.5012
Feb ’24€11.22
€12.24
+9.2%
16.9%€16.39€9.10€10.7712
Jan ’24€10.31
€12.82
+24.3%
18.2%€17.38€9.66€9.8111
Dec ’23€10.55
€12.82
+21.6%
18.2%€17.38€9.66€8.4811
Nov ’23€10.31
€12.71
+23.3%
22.4%€18.23€9.12€8.3911

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

ALM

€8.40

7D

-0.5%

1Y

0%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.30

7D

4.2%

1Y

85.6%

Bayer

€19.5b

Operates as a life science company worldwide.

BAYN

€19.77

7D

-3.7%

1Y

-39.4%